Ozempic^®

Boxed warning. Semaglutide caused thyroid C-cell tumors in rodents; it is unknown whether it causes thyroid tumors, including medullary thyroid carcinoma (MTC), in people. Do not use if you or a family member has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your prescriber about any lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.

Wegovy® is FDA approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. Ozempic® is FDA approved for type 2 diabetes; a prescriber may prescribe it off-label for weight management at their discretion, and off-label means the FDA has not approved that use. Both are dispensed only as the manufacturer's product.

• Serious risks include pancreatitis, gallbladder problems, kidney problems from dehydration, severe allergic reactions, worsening of diabetic eye disease, and low blood sugar (especially with insulin or sulfonylureas).
• Suicidal thoughts or behaviour have been reported with weight-management medicines; tell your prescriber about any history of depression and report any new or worsening mood changes.
• Semaglutide slows stomach emptying and can affect how other oral medicines are absorbed; it may also increase the risk of aspiration during procedures under anaesthesia. Tell any clinician treating you.
• Do not use if pregnant; stop at least two months before a planned pregnancy.
• Common side effects: nausea, diarrhoea, vomiting, constipation, stomach pain, headache, tiredness, dizziness, heartburn.

This is not a complete list of side effects, warnings, or interactions. Read the full prescribing information or medication guide, and talk to your prescriber or pharmacist. Report side effects to the FDA at 1-800-FDA-1088.